Trial Profile
A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab Emtansine Versus Lapatinib Plus Capecitabine in Chinese Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 05 May 2023 Status changed from active, no longer recruiting to completed.
- 10 Jan 2023 Planned End Date changed from 30 Oct 2022 to 31 Jan 2023.
- 13 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Oct 2022.